<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）的股票在周一由 Citizens Jmp 的研究分析师重新发布了 “市场表现优于大盘” 的评级，Benzinga 报道。他们目前对该股票的目标价格为 7.00 美元，低于之前的 10.00 美元目标价格。Citizens Jmp 的价格目标指向该股票当前价格的潜在上涨幅度为 105.28%。</p>
<p>MDXG 已经成为其他多份报告的主题。瑞银集团在 2 月 23 日的报告中对 MiMedx Group 的股票设定了 10.00 美元的目标价格。华尔街 Zen 在 2 月 28 日的报告中将 MiMedx Group 的股票评级从 “强力买入” 下调至 “买入”。Cantor Fitzgerald 在 2 月 17 日的报告中将 MiMedx Group 的股票目标价格从 12.00 美元下调至 8.00 美元，并对该股票给予了 “超配” 评级。Craig Hallum 在周五的报告中将 MiMedx Group 的股票目标价格从 10.00 美元下调至 7.00 美元，并对该股票给予了 “买入” 评级。最后，花旗集团在 2 月 23 日的报告中开始覆盖 MiMedx Group 的股票，并对该股票给予了 “市场表现优于大盘” 的评级。六位分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 8.67 美元。</p>
<p><strong>查看我们对 MiMedx Group 的最新分析</strong></p>
<h2>MiMedx Group 股票表现</h2>
<p>纳斯达克 MDXG 的股票在周一开盘价为 3.41 美元。该公司的债务与股本比率为 0.06，速动比率为 3.92，流动比率为 4.32。该公司的市值为 5.0662 亿美元，市盈率为 10.66，贝塔值为 1.65。该公司的 50 日移动平均线为 4.46 美元，200 日移动平均线为 5.85 美元。MiMedx Group 的 52 周低点为 3.31 美元，52 周高点为 7.99 美元。</p>
<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最后一次公布季度财报是在 2 月 25 日，报告显示该季度每股收益（EPS）为 0.14 美元，超出分析师的共识预期 0.09 美元，超出幅度为 0.05 美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 29.37%。该季度的收入为 1.181 亿美元，而共识预期为 1.0678 亿美元。整体来看，分析师预计 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
<h2>机构投资者对 MiMedx Group 的看法</h2>
<p>几家大型投资者最近增加或减少了对该股票的持股。先锋集团在第四季度将其在 MiMedx Group 的持股增加了 5.6%。先锋集团目前拥有 7184262 股该公司的股票，价值 48637000 美元，在此期间又购买了 382623 股。道富集团在第四季度将其在 MiMedx Group 的持股增加了 6.1%。道富集团目前拥有 3813796 股该公司的股票，价值 25819000 美元，在此期间又购买了 219190 股。First Light Asset Management LLC 在第三季度将其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 目前拥有 3652952 股该公司的股票，价值 25498000 美元，在此期间又购买了 1725458 股。Dimensional Fund Advisors LP 在第四季度将其在 MiMedx Group 的持股增加了 4.1%。Dimensional Fund Advisors LP 目前拥有 2479369 股该公司的股票，价值 16786000 美元，在此期间又购买了 97036 股。最后，Renaissance Technologies LLC 在第四季度将其在 MiMedx Group 的持股增加了 22.8%。Renaissance Technologies LLC 目前拥有 2467065 股该公司的股票，价值 16702000 美元，在此期间又购买了 458838 股。79.15% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 MiMedx Group</h2>
<p>（获取免费报告）</p>
<p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的纯化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
<p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 MiMedx Group 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 MiMedx Group 吗？</h2>
<p>在你考虑 MiMedx Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXG

<p>Citizens Jmp 重申了对 MiMedx Group (NASDAQ:MDXG) 的 “市场跑赢大盘” 评级，调整后的目标价为 7.00 美元，低于之前的 10.00 美元。这个目标价暗示从当前股价来看有 105.28% 的潜在上涨空间。其他分析师也调整了对 MiMedx Group 的评级和目标价，普遍评级为 “适度买入”，平均目标价为 8.67 美元。该公司报告的季度每股收益为 0.14 美元，超出预期，市值为 5.0662 亿美元</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report)'s stock had its &#34;market outperform&#34; rating reissued by research analysts at Citizens Jmp in a research note issued to investors on Monday,Benzinga reports. They currently have a $7.00 target price on the stock, down from their prior target price of $10.00. Citizens Jmp's price objective points to a potential upside of 105.28% from the stock's current price.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）的股票在周一由 Citizens Jmp 的研究分析师重新发布了 “市场表现优于大盘” 的评级，Benzinga 报道。他们目前对该股票的目标价格为 7.00 美元，低于之前的 10.00 美元目标价格。Citizens Jmp 的价格目标指向该股票当前价格的潜在上涨幅度为 105.28%。</p>
</div><p>MDXG has been the topic of a number of other reports. UBS Group set a $10.00 target price on shares of MiMedx Group in a report on Monday, February 23rd. Wall Street Zen downgraded shares of MiMedx Group from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, February 28th. Cantor Fitzgerald reduced their target price on shares of MiMedx Group from $12.00 to $8.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, February 17th. Craig Hallum reduced their target price on shares of MiMedx Group from $10.00 to $7.00 and set a &#34;buy&#34; rating on the stock in a report on Friday. Finally, Citigroup started coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a &#34;market outperform&#34; rating on the stock. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.67.</p>
<div class="lb-trans"><p>MDXG 已经成为其他多份报告的主题。瑞银集团在 2 月 23 日的报告中对 MiMedx Group 的股票设定了 10.00 美元的目标价格。华尔街 Zen 在 2 月 28 日的报告中将 MiMedx Group 的股票评级从 “强力买入” 下调至 “买入”。Cantor Fitzgerald 在 2 月 17 日的报告中将 MiMedx Group 的股票目标价格从 12.00 美元下调至 8.00 美元，并对该股票给予了 “超配” 评级。Craig Hallum 在周五的报告中将 MiMedx Group 的股票目标价格从 10.00 美元下调至 7.00 美元，并对该股票给予了 “买入” 评级。最后，花旗集团在 2 月 23 日的报告中开始覆盖 MiMedx Group 的股票，并对该股票给予了 “市场表现优于大盘” 的评级。六位分析师对该股票给予了买入评级，一位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 8.67 美元。</p>
</div><p><strong>View Our Latest Analysis on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>查看我们对 MiMedx Group 的最新分析</strong></p>
</div><h2>MiMedx Group Stock Performance</h2>
<div class="lb-trans"><h2>MiMedx Group 股票表现</h2>
</div><p>Shares of NASDAQ MDXG opened at $3.41 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The company has a market cap of $506.62 million, a P/E ratio of 10.66 and a beta of 1.65. The firm's fifty day moving average is $4.46 and its two-hundred day moving average is $5.85. MiMedx Group has a 52-week low of $3.31 and a 52-week high of $7.99.</p>
<div class="lb-trans"><p>纳斯达克 MDXG 的股票在周一开盘价为 3.41 美元。该公司的债务与股本比率为 0.06，速动比率为 3.92，流动比率为 4.32。该公司的市值为 5.0662 亿美元，市盈率为 10.66，贝塔值为 1.65。该公司的 50 日移动平均线为 4.46 美元，200 日移动平均线为 5.85 美元。MiMedx Group 的 52 周低点为 3.31 美元，52 周高点为 7.99 美元。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. The company had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. As a group, analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最后一次公布季度财报是在 2 月 25 日，报告显示该季度每股收益（EPS）为 0.14 美元，超出分析师的共识预期 0.09 美元，超出幅度为 0.05 美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 29.37%。该季度的收入为 1.181 亿美元，而共识预期为 1.0678 亿美元。整体来看，分析师预计 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On MiMedx Group</h2>
<div class="lb-trans"><h2>机构投资者对 MiMedx Group 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company's stock valued at $48,637,000 after buying an additional 382,623 shares during the period. State Street Corp boosted its position in MiMedx Group by 6.1% in the 4th quarter. State Street Corp now owns 3,813,796 shares of the company's stock valued at $25,819,000 after buying an additional 219,190 shares during the period. First Light Asset Management LLC boosted its position in MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock valued at $25,498,000 after buying an additional 1,725,458 shares during the period. Dimensional Fund Advisors LP boosted its position in MiMedx Group by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company's stock valued at $16,786,000 after buying an additional 97,036 shares during the period. Finally, Renaissance Technologies LLC boosted its position in MiMedx Group by 22.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,467,065 shares of the company's stock valued at $16,702,000 after buying an additional 458,838 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该股票的持股。先锋集团在第四季度将其在 MiMedx Group 的持股增加了 5.6%。先锋集团目前拥有 7184262 股该公司的股票，价值 48637000 美元，在此期间又购买了 382623 股。道富集团在第四季度将其在 MiMedx Group 的持股增加了 6.1%。道富集团目前拥有 3813796 股该公司的股票，价值 25819000 美元，在此期间又购买了 219190 股。First Light Asset Management LLC 在第三季度将其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 目前拥有 3652952 股该公司的股票，价值 25498000 美元，在此期间又购买了 1725458 股。Dimensional Fund Advisors LP 在第四季度将其在 MiMedx Group 的持股增加了 4.1%。Dimensional Fund Advisors LP 目前拥有 2479369 股该公司的股票，价值 16786000 美元，在此期间又购买了 97036 股。最后，Renaissance Technologies LLC 在第四季度将其在 MiMedx Group 的持股增加了 22.8%。Renaissance Technologies LLC 目前拥有 2467065 股该公司的股票，价值 16702000 美元，在此期间又购买了 458838 股。79.15% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About MiMedx Group</h2>
<div class="lb-trans"><h2>关于 MiMedx Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的纯化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等品牌命名的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MiMedx Group 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MiMedx Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Citizens Jmp 重申对 MiMedx Group（NASDAQ:MDXG）的 “市场表现优异” 评级